FDA Panel Strongly Backs Protein-Based Novavax COVID Vaccine FDA Panel Strongly Backs Protein-Based Novavax COVID Vaccine

FDA advisers voted 21-0 in favor of the Novavax COVID vaccine, which is based on older, more conventional technology than mRNA shots. Advocates for this shot see it as likely to win over some vaccine-hesitant people.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Infectious Diseases News Source Type: news